Roche Receives FDA and CE-IVDR Approvals for Expanded HER2 Diagnostic Applications in Cancer Treatment
Key Insights
Roche has secured FDA approval for the first companion diagnostic test to identify HER2 (search)-positive biliary tract cancer (search) patients eligible for ZIIHERA treatment.
The company also received CE-IVDR approval for two label expansions of its VENTANA HER2 (search) (4B5) assay, including assessment of HER2-ultralow status in metastatic breast cancer (search).
These approvals address a critical unmet need in cancer diagnostics, as no approved HER2 (search) test previously existed for biliary tract cancer (search) patients.
Roche has achieved significant regulatory milestones with the approval of expanded applications for its HER2 (search) diagnostic tests, addressing critical gaps in cancer patient identification for targeted therapies. The U.S. Food and Drug Administration has approved an expansion of the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test label to include biliary tract cancer (search) (BTC), marking the first FDA-approved companion diagnostic for this indication.
First-in-Class Diagnostic for Biliary Tract Cancer
The PATHWAY HER2 (search) (4B5) test now serves as the first and only FDA-approved companion diagnostic to assess HER2-positive status and identify BTC patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii (search)). This approval addresses a significant unmet medical need, as no approved and validated HER2 test existed to identify eligible BTC patients until this expanded label approval.
HER2 (search) is a receptor protein expressed in a variety of cancers and serves as a predictive biomarker to help determine if a patient will respond to HER2-targeted therapy. The availability of a validated diagnostic test is crucial for identifying patients who may benefit from targeted treatment approaches.
European Regulatory Approval for Dual Indications
Concurrently, Roche has received CE-IVDR approval for two label expansions of its VENTANA HER2 (search) (4B5) Rabbit Monoclonal Primary Antibody RxDx assay. The VENTANA HER2 (4B5) test is now CE-IVDR approved to aid in assessing HER2-ultralow status in metastatic breast cancer (search) patients who may be eligible for treatment with ENHERTU.
Additionally, the test is approved to help identify patients with previously treated, unresectable, or metastatic HER2 (search)-positive biliary tract cancer (search) who may be eligible for treatment with ZIIHERA. This dual approval expands the diagnostic utility of the assay across multiple cancer types and treatment scenarios.
Clinical Impact and Treatment Matching
These regulatory approvals represent a significant advancement in precision oncology, enabling healthcare providers to accurately identify patients who may benefit from specific HER2 (search)-targeted therapies. The diagnostic tests will facilitate appropriate patient selection for ENHERTU in HER2-ultralow metastatic breast cancer (search) and ZIIHERA in HER2-positive biliary tract cancer (search).
The approvals underscore the importance of companion diagnostics in modern cancer care, where treatment decisions increasingly depend on molecular characteristics of tumors rather than solely on cancer type and stage. The availability of validated diagnostic tests ensures that patients receive the most appropriate targeted therapies based on their tumor's HER2 (search) expression profile.